Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIMCVE:GMNTSE:OLYNYSEARCA:XLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$9.01-1.7%$9.12$0.06▼$14.93$6.88M0.94562,302 shs1,953 shsGMNGobiMinC$1.83C$1.83C$0.20▼C$1.84C$89.78M0.7628,832 shs167,000 shsOLYOlympia Financial GroupC$121.00+1.3%C$111.31C$90.50▼C$124.00C$291.17M0.271,918 shs552 shsXLYConsumer Discretionary Select Sector SPDR Fund$221.67+0.8%$210.53$166.48▼$240.28$22.81B1.184.20 million shs1.72 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+1.61%+1.50%-0.78%-22.95%-74.84%GMNGobiMin0.00%0.00%0.00%0.00%0.00%OLYOlympia Financial Group-0.13%-1.24%+6.90%+15.26%+32.00%XLYConsumer Discretionary Select Sector SPDR Fund+0.80%+3.27%+2.66%+15.17%+17.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.9707 of 5 stars3.50.00.00.02.41.70.0GMNGobiMinN/AN/AN/AN/AN/AN/AN/AN/AOLYOlympia Financial Group3.0403 of 5 stars2.50.02.50.01.93.31.3XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.002,952.16% UpsideGMNGobiMin 0.00N/AN/AN/AOLYOlympia Financial Group 3.00BuyC$147.9122.24% UpsideXLYConsumer Discretionary Select Sector SPDR Fund 2.65Moderate Buy$221.26-0.18% DownsideCurrent Analyst Ratings BreakdownLatest GMN, OLY, XLY, and AIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025OLYOlympia Financial GroupFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuyC$147.91(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K47.15N/AN/A$0.20 per share45.05GMNGobiMinC$28.61K3,137.84C$3.22 per share0.57C$1.89 per share0.97OLYOlympia Financial GroupC$102.64M2.84C$10.38 per share11.66C$16.72 per share7.24XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/AGMNGobiMin-C$10.43M-C$0.29N/A∞N/A83,354.28%-13.01%-3.82%N/AOLYOlympia Financial GroupC$24.45MC$10.1611.91∞N/A23.82%64.95%35.88%N/AXLYConsumer Discretionary Select Sector SPDR FundN/AN/A27.10∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AGMNGobiMinN/A4.35%N/AN/AN/AOLYOlympia Financial GroupC$7.205.95%N/A70.86%N/AXLYConsumer Discretionary Select Sector SPDR Fund$1.820.82%N/AN/AN/ALatest GMN, OLY, XLY, and AIM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/19/2025OLYOlympia Financial GroupMonthlyC$0.606.28%6/19/20256/30/20256/30/20255/21/2025OLYOlympia Financial GroupMonthlyC$0.606.99%5/21/20255/30/20255/30/20254/17/2025OLYOlympia Financial GroupMonthlyC$0.606.94%4/17/20254/30/20254/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75GMNGobiMin0.5833.6331.98OLYOlympia Financial Group6.003.321.59XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%GMNGobiMinN/AOLYOlympia Financial Group1.17%XLYConsumer Discretionary Select Sector SPDR Fund69.93%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%GMNGobiMinN/AOLYOlympia Financial Group34.63%XLYConsumer Discretionary Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableGMNGobiMinN/A49.06 millionN/ANot OptionableOLYOlympia Financial Group3252.41 millionN/ANot OptionableXLYConsumer Discretionary Select Sector SPDR Fund147,000102.90 millionN/ANot OptionableGMN, OLY, XLY, and AIM HeadlinesRecent News About These CompaniesS&P 500 consumer discretionary sector jumps 8.9% in Q2, Royal Caribbean Cruises, Carnival, Lululemon Athletica among top moversJuly 3 at 4:57 AM | seekingalpha.comWeekly Economic Snapshot: Record Highs Amid Rising Inflation & Conflicting SentimentJune 30 at 7:13 AM | etftrends.comENorwegian Cruise Line Stock: Is NCLH Underperforming the Consumer Discretionary Sector?June 26, 2025 | msn.comConsumer Discretionary Select Sector SPDR ETF declares quarterly distribution of $0.4470June 23, 2025 | msn.comAmcor Stock: Is AMCR Underperforming the Consumer Discretionary Sector?June 23, 2025 | finance.yahoo.comConsumer Rebound Boosts Outlook for Discretionary ETFsJune 16, 2025 | zacks.comWeekly Economic Snapshot: Inflation Edges Up While Sentiment ReboundsJune 16, 2025 | etftrends.comESector ETFs Set to Gain as Inflation Cools in MayJune 12, 2025 | zacks.comIs Consumer Discretionary a Dead End? These 3 Stocks Say No (XLY)...June 11, 2025 | marketbeat.comNintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? (XLY)...June 11, 2025 | marketbeat.comConsumer Discretionary ETFs Set for a Comeback?June 11, 2025 | zacks.comWeekly Economic Snapshot: Inflation Cools While Sentiment Cautiously ClimbsJune 2, 2025 | etftrends.comEShould You Invest in the Consumer Discretionary Select Sector SPDR ETF (XLY)?June 2, 2025 | zacks.comWeekly Economic Snapshot: Inflation Relief Meets Consumer WoesMay 19, 2025 | etftrends.comE3 Dividend-Friendly Consumer Discretionary Stocks With UpsideMay 19, 2025 | dividendstocks.comDMost and least shorted S&P 500 consumer discretionary stocks in AprilMay 18, 2025 | seekingalpha.com3 ETF Strategies to Follow on Temporary U.S.-China Trade DealMay 12, 2025 | zacks.comOil Slumps to Below $60: ETFs to GainMay 5, 2025 | zacks.comWeekly Economic Snapshot: Solid Jobs Amid GDP Contraction & Crashing ConfidenceMay 5, 2025 | etftrends.comE7 of 17 S&P 500 consumer discretionary stocks beat estimates - Earnings ScoreboardMay 4, 2025 | msn.comPCE Report Preview: TLT, Sector ETFs in FocusApril 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyBy Jeffrey Neal Johnson | June 10, 2025View ASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyGMN, OLY, XLY, and AIM Company DescriptionsAIM ImmunoTech NYSE:AIM$9.01 -0.16 (-1.74%) As of 12:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.GobiMin CVE:GMNC$1.83 0.00 (0.00%) As of 03/8/2023GobiMin Inc., together with its subsidiaries, engages in investment in equity, debt, or other securities in China. The company operates in two segments, Investment Business and Mining Business. It is also involved in the property investment, holding, and leasing activities; and development, exploration, and exploitation of gold property, as well as provision of business and consultancy services. The company is based in Montreal, Canada. GobiMin Inc. operates as a subsidiary of Belmont Holdings Group Limited.Olympia Financial Group TSE:OLYC$121.00 +1.50 (+1.26%) As of 10:43 AM EasternOlympia Financial Group Inc is engaged in providing financial services. The company's operating segments are Private Health Services Plan division which markets, sells and administers health and dental benefits to business owners; Investment Account Services division specializes in registered account administration; The Currency and Global Payments division provides corporations and private clients a personalized service for buying and selling foreign currencies; The Exempt Edge division is focused on Onboarding fees; The Corporate and Shareholder Services division, which acts as a cost centre and the Corporate Division.Consumer Discretionary Select Sector SPDR Fund NYSEARCA:XLY$221.67 +1.66 (+0.75%) As of 12:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Consumer Discretionary Select Sector SPDR Fund seeks to provide investment results that correspond generally to the price and yield performance of the Consumer Discretionary Select Sector Index (the Index). The Index includes companies from the following industries, media; retail (specialty, multiline, Internet and catalog); hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure equipment and products; and diversified consumer services. The Fund's investment advisor is SSgA Funds Management, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
